Emerging peptide-based nanovaccines: From design synthesis to defense against cancer and infection - 13/01/23
Abstract |
Peptide-based vaccines, which form one of the most potent vaccine platforms, offer exclusive advantages over classical vaccines that use whole organisms or proteins. However, peptides alone are still poor stability and weak immunogenicity, thus need a delivery system that can overcome these shortcomings. Currently, nanotechnology has been extensively utilized to address this issue. Nanovaccines, as new formulations of vaccines using nanoparticles (NPs) as carriers or adjuvants, are undergoing development instead of conventional vaccines. Indeed, peptide-based nanovaccine is a rapidly developing field of research that is emerging out of the confluence of antigenic peptides with the nano-delivery system. In this review, we shed light on the rational design and preparation strategies based on various nanomaterials of peptide-based nanovaccines, and we spotlight progress in the development of peptide-based nanovaccines against cancer and infectious diseases. Finally, the future prospects for development of peptide-based nanovaccines are presented.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Peptide-based nanovaccines have exclusive merits to elicit systemic immune responses. |
• | Different nanomaterials involve in the formulation of peptide-based nanovaccines. |
• | Polymer, lipid, and inorganic-based nanoparticles are potential vaccine candidate materials. |
• | Peptide-based nanovaccines are a promising therapeutic strategy in cancer and infectious diseases. |
Abbreviations : NPs, APCs, DCs, SARS, HIV, HPV, GAS, PLGA, ATP, DDAB, TMC, CTL, VADS, PAMPs, PRR, TLRs, LCPs, CaP, TSA, TCR, SC, IM, HA, HTLV-1
Keywords : Peptide-based vaccines, Nanovaccine, Delivery system, Nanomaterials, Immune response
Plan
Vol 158
Article 114117- février 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?